Cancer Immunotherapy: CRISPR/Cas9-Engineered CAR-T Cells for Solid Tumors
CRISPR/Cas9-engineered CAR-T cells, a revolutionary approach in cancer immunotherapy, hold immense promise for treating solid tumors. By leveraging the precision of CRISPR/Cas9 gene editing, these engineered immune cells are designed to target and eliminate cancer cells with enhanced specificity and efficacy. This article explores the scientific advancements, Herausforderungen, and potential clinical applications of CRISPR/Cas9-engineered CAR-T cells, providing insights into a promising frontier in cancer treatment.